Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 26, 2020updated 06 Dec 2021 9:48am

Leica Biosystems and Bio-Techne launch CE-IVD marked detection kit

Leica Biosystems and Bio-Techne have launched the CE-IVD marked RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform in Europe.

Leica Biosystems and Bio-Techne have launched the CE-IVD marked RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform in Europe.

Bio-Techne’s RNAscope together with Leica’s platform will enable pathologists to access the leading applications to support their diagnostics labs.

The technology improves on traditional ISH methodologies through higher target sensitivity and specificity. It detects RNA expression patterns and localisation at the single-cell level with spatial and morphologic context.

Bio-Techne Diagnostics and Genomics Segment president Kim Kelderman said: “We are excited to expand our Leica partnership with the launch of our CE-IVD marked detection kit in Europe.

“Diagnostic labs will now have access to the fully automated RNAscope technology, providing pathologists with a powerful new tool to evaluate biomarkers involved in cancer, infection and other important human diseases.”

The RNAscope technology is said to be highly sensitive and specific due to its double Z probe design.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

It provides an extremely high signal-to-noise ratio of staining in various tissue types and enables diagnostic pathologists to visualise, localise and quantify biomarker expression simultaneously.

Leica Biosystems Advanced Staining and Imaging global vice-president Colin White said: “During these difficult times and the ever-changing world due to Covid-19, we are excited about this innovative product as it delivers the benefit of improved workflow, reduced hands-on time and provides our European pathology partners an additional tool in their IVD toolbox against various diseases.”

Last month, Leica Biosystems received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for its Aperio ImageScope DX Viewer for remote diagnosis of Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU